Literature DB >> 17132628

FOXO3a induces differentiation of Bcr-Abl-transformed cells through transcriptional down-regulation of Id1.

Kim U Birkenkamp1, Abdelkader Essafi, Kristan E van der Vos, Marco da Costa, Rosaline C-Y Hui, Frank Holstege, Leo Koenderman, Eric W-F Lam, Paul J Coffer.   

Abstract

Leukemic transformation often requires activation of protein kinase B (PKB/c-Akt) and is characterized by increased proliferation, decreased apoptosis, and a differentiation block. PKB phosphorylates and inactivates members of the FOXO subfamily of Forkhead transcription factors. It has been suggested that hyperactivation of PKB maintains the leukemic phenotype through actively repressing FOXO-mediated regulation of specific genes. We have found expression of the transcriptional repressor Id1 (inhibitor of DNA binding 1) to be abrogated by FOXO3a activation. Inhibition of PKB activation or growth factor deprivation also resulted in strong down-regulation of Id1 promoter activity, Id1 mRNA, and protein expression. Id1 is highly expressed in Bcr-Abl-transformed K562 cells, correlating with high PKB activation and FOXO3a phosphorylation. Inhibition of Bcr-Abl by the chemical inhibitor STI571 resulted in activation of FOXO3a and down-regulation of Id1 expression. By performing chromatin immunoprecipitation assays and promoter-mutation analysis, we demonstrate that FOXO3a acts as a transcriptional repressor by directly binding to the Id1 promoter. STI571 treatment, or expression of constitutively active FOXO3a, resulted in erythroid differentiation of K562 cells, which was inhibited by ectopic expression of Id1. Taken together our data strongly suggest that high expression of Id1, through PKB-mediated inhibition of FOXO3a, is critical for maintenance of the leukemic phenotype.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17132628     DOI: 10.1074/jbc.M606669200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  39 in total

Review 1.  Inhibition of Ras-mediated signaling pathways in CML stem cells.

Authors:  Jessika Bertacchini; Neda Ketabchi; Laura Mediani; Silvano Capitani; Sandra Marmiroli; Najmaldin Saki
Journal:  Cell Oncol (Dordr)       Date:  2015-10-12       Impact factor: 6.730

Review 2.  Regulation of B-cell proliferation and differentiation by pre-B-cell receptor signalling.

Authors:  Sebastian Herzog; Michael Reth; Hassan Jumaa
Journal:  Nat Rev Immunol       Date:  2009-03       Impact factor: 53.106

Review 3.  Role of the forkhead transcription factor FOXO-FOXM1 axis in cancer and drug resistance.

Authors:  Fung Zhao; Eric W-F Lam
Journal:  Front Med       Date:  2012-11-03       Impact factor: 4.592

Review 4.  FoxO3a and disease progression.

Authors:  Richard Seonghun Nho; Polla Hergert
Journal:  World J Biol Chem       Date:  2014-08-26

Review 5.  The ID proteins: master regulators of cancer stem cells and tumour aggressiveness.

Authors:  Anna Lasorella; Robert Benezra; Antonio Iavarone
Journal:  Nat Rev Cancer       Date:  2014-01-20       Impact factor: 60.716

Review 6.  Deciphering the role of forkhead transcription factors in cancer therapy.

Authors:  Jer-Yen Yang; Mien-Chie Hung
Journal:  Curr Drug Targets       Date:  2011-08       Impact factor: 3.465

7.  Dual blocking of mTor and PI3K elicits a prodifferentiation effect on glioblastoma stem-like cells.

Authors:  Jun Sunayama; Atsushi Sato; Ken-ichiro Matsuda; Ken Tachibana; Kaori Suzuki; Yoshitaka Narita; Soichiro Shibui; Kaori Sakurada; Takamasa Kayama; Arata Tomiyama; Chifumi Kitanaka
Journal:  Neuro Oncol       Date:  2010-09-22       Impact factor: 12.300

Review 8.  FoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis.

Authors:  Zainab Jagani; Amrik Singh; Roya Khosravi-Far
Journal:  Biochim Biophys Acta       Date:  2007-10-16

Review 9.  A new fork for clinical application: targeting forkhead transcription factors in cancer.

Authors:  Jer-Yen Yang; Mien-Chie Hung
Journal:  Clin Cancer Res       Date:  2009-02-01       Impact factor: 12.531

10.  A novel acetylenic tricyclic bis-(cyano enone) potently induces phase 2 cytoprotective pathways and blocks liver carcinogenesis induced by aflatoxin.

Authors:  Karen Liby; Mark M Yore; Bill D Roebuck; Karen J Baumgartner; Tadashi Honda; Chitra Sundararajan; Hidenori Yoshizawa; Gordon W Gribble; Charlotte R Williams; Renee Risingsong; Darlene B Royce; Albena T Dinkova-Kostova; Katherine K Stephenson; Patricia A Egner; Melinda S Yates; John D Groopman; Thomas W Kensler; Michael B Sporn
Journal:  Cancer Res       Date:  2008-08-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.